Longevity and Stress Resistance

长寿和抗压能力

基本信息

项目摘要

DESCRIPTION (provided by applicant): The overall theme of this project is to test the hypothesis that life span extension, longevity and stress resistance are mediated by common mechanisms. Growing lines of evidence suggest that the longevity of a wide variety of organisms, from yeast to worms and flies to mammals, is regulated by defined molecular mechanisms, including Sir2, an NAD-dependent histone deacetylase, and the adenylyl cyclase-protein kinase A pathway. A major limitation to understanding the key regulatory mechanisms responsible for causing the adverse effects of aging, or conversely, those that extend longevity, is the lack of animal models which exhibit prolonged lifespan and which do not develop cardiomyopathy or osteoporosis or other end- points, which are normally observed with aging. The model, which is accepted best for increasing longevity from yeast to primates, is caloric restriction. Relatively few other models for longevity are available. In this connection, we have recently identified a novel, genetically engineered animal model, which lives longer than wild type animals and does not exhibit many of the cardiac and osteoporotic features of old age, i.e., mice with the adenylyl cyclase (AC) type 5 "knocked out" (ACS KO). It is our contention that examining mechanisms that are unique to the ACS KO model will provide important insight into the aging process and, potentially, mechanisms which might be utilized to reverse this process. Projects 1 and 2 examine these mechanisms in this mouse model. In addition, Project 3 has developed and will study other mouse models of aging and stress resistance, related to Sir2alpha. The central hypothesis in that project is that Sir2alpha mediates anti-aging as well as cell protective effects in the heart in vivo. These 3 projects are supported by 5 cores: Administration/Physiology; Animal Care; Genomics/Proteomics; Bioinformatics/Biostatistics; Pathology. This Program Project has major implications for public health. The disability associated with aging has a major impact on the public health and the U.S. economy. Finding molecular switches, such as the ones described in this project, could ameliorate disability with aging and would be a major step forward.
描述(由申请人提供):该项目的总体主题是检验以下假设:寿命延长,寿命和压力抵抗力是由共同机制介导的。越来越多的证据表明,从酵母到蠕虫,果蝇再到哺乳动物的各种生物的寿命受定义的分子机制调节,包括SIR2,NAD依赖性组蛋白脱乙酰基酶和腺苷酸环化酶蛋白酶酶A酶A途径。理解负责导致衰老的不利影响的关键调节机制的主要局限性,或者相反,那些延长寿命的不良影响是缺乏表现出延长寿命并且不发展心肌病或骨质疏松或其他端点的动物模型,这些模型正常观察到衰老。该模型是最适合增加酵母到灵长类动物的寿命的最佳选择的模型,这是热量限制。提供相对较少的寿命型号。在这方面,我们最近确定了一种新型的基因工程动物模型,该模型的寿命比野生型动物更长,并且没有表现出许多老年的心脏和骨质疏松性特征,即带有腺苷酸环化酶(AC)5“敲除”(ACS KO)的小鼠(AC)。我们的论点是,检查ACS KO模型独有的机制将为衰老过程提供重要的见解,并可能利用可能用于扭转这一过程的机制。项目1和2在此鼠标模型中检查了这些机制。此外,项目3已开发并将研究与sir2alpha相关的其他小鼠衰老和压力抗性的模型。该项目的中心假设是sir2alpha介导了体内心脏中心的抗衰老和细胞保护作用。这三个项目得到了5个核心的支持:行政/生理学;动物护理;基因组学/蛋白质组学;生物信息学/生物统计学;病理。该计划项目对公共卫生有重大影响。与衰老相关的残疾对公共卫生和美国经济产生了重大影响。查找分子开关(例如本项目中描述的开关)可能会随着衰老而改善残疾,这将是前进的主要一步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN F VATNER其他文献

STEPHEN F VATNER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN F VATNER', 18)}}的其他基金

A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
一种治疗阿尔茨海默病的新型 5 型腺苷酸环化酶药理抑制剂
  • 批准号:
    10608477
  • 财政年份:
    2022
  • 资助金额:
    $ 182.23万
  • 项目类别:
Skeletal Muscle and Brown Adipose Mechanisms Mediating Cardiovascular Risk Factor Protection in RGS14 KO
RGS14 KO 中骨骼肌和棕色脂肪机制介导心血管危险因素保护
  • 批准号:
    9900047
  • 财政年份:
    2017
  • 资助金额:
    $ 182.23万
  • 项目类别:
Angiogenesis Protection Induced by sFRP3 Myocyte/Vascular Cross-Talk
sFRP3 肌细胞/血管交互作用诱导的血管生成保护
  • 批准号:
    9900045
  • 财政年份:
    2017
  • 资助金额:
    $ 182.23万
  • 项目类别:
Vascular Protection in Hibernating Woodchucks
冬眠土拨鼠的血管保护
  • 批准号:
    9020511
  • 财政年份:
    2016
  • 资助金额:
    $ 182.23万
  • 项目类别:
RGS 14 Disruption, Vascular Effects Leading to Cardioprotection
RGS 14 破坏、血管效应导致心脏保护
  • 批准号:
    8888575
  • 财政年份:
    2015
  • 资助金额:
    $ 182.23万
  • 项目类别:
RGS 14 Disruption, Vascular Effects Leading to Cardioprotection
RGS 14 破坏、血管效应导致心脏保护
  • 批准号:
    9102537
  • 财政年份:
    2015
  • 资助金额:
    $ 182.23万
  • 项目类别:
Intrinsic Vascular Smooth Muscle Cell Stiffness
内在血管平滑肌细胞硬度
  • 批准号:
    8764029
  • 财政年份:
    2013
  • 资助金额:
    $ 182.23万
  • 项目类别:
Longevity and Stress Resistance
长寿和抗压能力
  • 批准号:
    8682004
  • 财政年份:
    2013
  • 资助金额:
    $ 182.23万
  • 项目类别:
Skeletal Muscle Basis for Improved Exercise Endurance in RGS14 KO
RGS14 KO 中提高运动耐力的骨骼肌基础
  • 批准号:
    9513046
  • 财政年份:
    2011
  • 资助金额:
    $ 182.23万
  • 项目类别:
Skeletal Muscle Basis for Improved Exercise Endurance in AC5 KO
AC5 KO 中提高运动耐力的骨骼肌基础
  • 批准号:
    8193326
  • 财政年份:
    2011
  • 资助金额:
    $ 182.23万
  • 项目类别:

相似国自然基金

基于sIgA的V(D)J结构多样性探索腺病毒载体鼻喷新冠奥密克戎疫苗诱导的呼吸道粘膜免疫原性特征
  • 批准号:
    82302607
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
新型腺病毒载体Ad49L介导的高水平干扰素α抑制疫苗体液免疫的机制
  • 批准号:
    82302001
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
新型腺病毒载体疫苗长效免疫机制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
新型腺病毒载体疫苗长效免疫机制
  • 批准号:
    82271868
  • 批准年份:
    2022
  • 资助金额:
    53.00 万元
  • 项目类别:
    面上项目
基于肠道腺病毒载体平台COVID-19粘膜疫苗的设计与筛选
  • 批准号:
    82161138001
  • 批准年份:
    2021
  • 资助金额:
    150 万元
  • 项目类别:
    国际(地区)合作与交流项目

相似海外基金

Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer
推进溶瘤腺病毒治疗胰腺癌的系统递送
  • 批准号:
    10734709
  • 财政年份:
    2023
  • 资助金额:
    $ 182.23万
  • 项目类别:
Lentivirus Construct Core
慢病毒构建核心
  • 批准号:
    10630391
  • 财政年份:
    2023
  • 资助金额:
    $ 182.23万
  • 项目类别:
Pulmonary endothelium targeted adenoviral gene therapy for the correction of mucopolysaccharidosis type I
肺内皮靶向腺病毒基因治疗纠正 I 型粘多糖贮积症
  • 批准号:
    10678053
  • 财政年份:
    2023
  • 资助金额:
    $ 182.23万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 182.23万
  • 项目类别:
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
ISPRI-HCP 的验证和改进:工艺相关蛋白质杂质免疫原性风险评估的创新平台
  • 批准号:
    10603538
  • 财政年份:
    2023
  • 资助金额:
    $ 182.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了